← Back to Search

Anti-metabolites

Tislelizumab + Chemotherapy for Gastric Cancer

Phase 3
Waitlist Available
Research Sponsored by BeiGene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Locally advanced unresectable or metastatic GC or GEJ carcinoma with histologically confirmed adenocarcinoma
Be older than 18 years old
Must not have
Diagnosed with gastric or GEJ adenocarcinoma with positive HER2
Active leptomeningeal disease or uncontrolled brain metastasis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 48 months
Awards & highlights
Pivotal Trial
Approved for 5 Other Conditions

Summary

This trial is testing a new treatment that combines an immune-boosting drug called tislelizumab with standard chemotherapy. It targets patients with advanced stomach cancer that cannot be removed by surgery and has spread to other parts of the body. The treatment works by helping the immune system find and destroy cancer cells.

Who is the study for?
Adults with inoperable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma can join this trial. They shouldn't have had systemic therapy for their condition yet but may have completed prior therapies without recurrence for at least 6 months. Participants need to be relatively fit (ECOG PS ≤ 1) and have good organ function.
What is being tested?
The study is testing Tislelizumab combined with chemotherapy against a placebo plus chemotherapy as the first-line treatment. It's a phase 3 trial where participants are randomly assigned to either group in equal numbers, and neither they nor the researchers know who gets which treatment (double-blind).
What are the potential side effects?
Tislelizumab could cause immune-related reactions, fatigue, nausea, liver issues, skin rash and increase infection risk. Chemotherapy agents like Cisplatin and Capecitabine might lead to digestive problems, nerve damage, low blood cell counts causing bruising or infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer is in the stomach or esophagus and cannot be surgically removed.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have stomach or junction cancer that is HER2 positive.
Select...
I have active cancer spread to the brain or its linings that is not under control.
Select...
I have previously been treated with drugs targeting immune checkpoints.
Select...
My stomach cancer is of a specific type (squamous cell, undifferentiated).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 48 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 48 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Survival (OS)
Secondary study objectives
Disease control rate (DCR)
Duration of response (DOR)
Overall response rate (ORR)
+3 more

Side effects data

From 2022 Phase 3 trial • 512 Patients • NCT03430843
31%
Anaemia
24%
Weight decreased
17%
Cough
16%
Decreased appetite
16%
Pyrexia
16%
Constipation
15%
Nausea
15%
Aspartate aminotransferase increased
14%
Hypoalbuminaemia
13%
Alanine aminotransferase increased
13%
Diarrhoea
13%
Fatigue
12%
Hyponatraemia
12%
Hypothyroidism
11%
Asthenia
11%
Vomiting
11%
Back pain
11%
Pneumonia
10%
Dyspnoea
10%
Pruritus
9%
Dysphagia
9%
Arthralgia
9%
Hypokalaemia
9%
Rash
8%
Insomnia
7%
Hyperglycaemia
7%
Blood alkaline phosphatase increased
7%
Productive cough
7%
Abdominal pain
6%
Malaise
5%
Lymphocyte count decreased
5%
Gastrooesophageal reflux disease
5%
White blood cell count increased
5%
Platelet count decreased
5%
Gamma-glutamyltransferase increased
5%
Hypoproteinaemia
5%
Hypertension
4%
Pneumonitis
4%
Stomatitis
4%
Blood bilirubin increased
4%
Hypotension
4%
Oedema peripheral
4%
Abdominal pain upper
4%
Abdominal distension
4%
Nasopharyngitis
4%
White blood cell count decreased
4%
Haemoptysis
4%
Cancer pain
4%
Dizziness
4%
Leukopenia
4%
Blood creatine phosphokinase MB increased
4%
Blood creatine phosphokinase increased
3%
Upper respiratory tract infection
3%
Myalgia
3%
Hypoglycaemia
3%
Hyperthyroidism
3%
Hypocalcaemia
3%
Dysphonia
3%
Hyperkalaemia
3%
C-reactive protein increased
2%
Upper gastrointestinal haemorrhage
2%
Hypochloraemia
2%
Hyperuricaemia
2%
Thrombocytopenia
2%
Oesophageal obstruction
2%
Neutrophil count decreased
1%
Pneumonia aspiration
1%
Tumour pain
1%
Hypercalcaemia
1%
Immune-mediated myositis
1%
Neutropenia
1%
Death
1%
Oesophageal fistula
1%
Multiple organ dysfunction syndrome
1%
Peripheral sensory neuropathy
1%
Oesophagomediastinal fistula
1%
Pulmonary haemorrhage
1%
Oesophageal stenosis
1%
Pleural effusion
1%
General physical health deterioration
1%
Pulmonary embolism
1%
Immune-mediated lung disease
1%
Sepsis
1%
Type 1 diabetes mellitus
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tislelizumab
Investigator Chosen Chemotherapy (ICC)

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Tislelizumab (BGB-A317) + chemotherapyExperimental Treatment5 Interventions
Tislelizumab and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-Fluorouracil regimens are used as the backbone chemotherapy.
Group II: Placebo + chemotherapyPlacebo Group5 Interventions
Placebo and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-FU regimens are used as the backbone chemotherapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tislelizumab
Not yet FDA approved
Cisplatin
FDA approved
Capecitabine
FDA approved
Oxaliplatin
FDA approved
5-FU
2014
Completed Phase 3
~3100

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for gastric cancer include chemotherapy, targeted therapy, and immunotherapy. Immunotherapy, particularly with agents like tislelizumab (an anti-PD-1 monoclonal antibody), works by blocking the PD-1 pathway, which cancer cells exploit to evade the immune system. By inhibiting this pathway, tislelizumab reactivates T-cells, allowing them to recognize and attack cancer cells. This mechanism is crucial for gastric cancer patients as it offers a novel approach to treatment, potentially improving survival rates and providing options for those who may not respond to traditional therapies.

Find a Location

Who is running the clinical trial?

BeiGeneLead Sponsor
200 Previous Clinical Trials
30,648 Total Patients Enrolled
Jin Wang, MDStudy DirectorBeiGene

Media Library

5-FU (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT03777657 — Phase 3
Gastric Cancer Research Study Groups: Tislelizumab (BGB-A317) + chemotherapy, Placebo + chemotherapy
Gastric Cancer Clinical Trial 2023: 5-FU Highlights & Side Effects. Trial Name: NCT03777657 — Phase 3
5-FU (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03777657 — Phase 3
~142 spots leftby Dec 2025